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Background: Current peptide vaccines may select suboptimal antigen-specific T-cells from polyclonal populations.
Results:Acombinatorial peptide library screenwas used to generate an optimal ligand that could preferentially activate a known
effective T-cell clonotype.
Conclusion: Rationally designed altered peptide ligands may enable the preferential selection of high quality, antigen-sensitive
T-cell clonotypes.
Significance: This proof-of-principle study could facilitate the development of more effective peptide vaccination strategies.
Altered peptide antigens that enhance T-cell immunogenicity
havebeenused to improvepeptide-basedvaccination fora rangeof
diseases. Although this strategy can prime T-cell responses of
greater magnitude, the efficacy of constituent T-cell clonotypes
within the primed population can be poor. To overcome this limi-
tation, we isolated a CD8 T-cell clone (MEL5) with an enhanced
ability to recognize the HLAA*0201-Melan A27–35 (HLAA*0201-
AAGIGILTV) antigen expressed on the surface of malignant mel-
anoma cells. We used combinatorial peptide library screening to
design anoptimal peptide sequence that enhanced functional acti-
vation of the MEL5 clone, but not other CD8 T-cell clones that
recognized HLA A*0201-AAGIGILTV poorly. Structural analysis
revealed the potential for new contacts between the MEL5 T-cell
receptor and the optimized peptide. Furthermore, the optimized
peptide was able to prime CD8 T-cell populations in peripheral
bloodmononuclear cell isolates frommultipleHLAA*0201 indi-
viduals that were capable of efficient HLA A*0201 melanoma
cell destruction. This proof-of-concept study demonstrates that
it is possible to design altered peptide antigens for the selection
of superiorT-cell clonotypeswith enhancedantigen recognition
properties.
The key aim of vaccination is to establish populations of
memory T-cells and B-cells expressing antigen receptors that
provide a rapid, robust targeted immune response. Antigen
receptors on B-cells undergo affinity maturation through a
process of somatic hypermutation that allows evolution toward
more effective responses over time. In contrast, the T-cell
receptor (TCR)3 is fixed on individual T-cell clonotypes.
Antigen-specific T-cells bearing heterodimeric  TCRs
play a pivotal role in adaptive immunity to pathogens and cel-
lular malignancies by recognizing short peptide fragments
bound to major histocompatibility complex (MHC) molecules
on the target cell surface (1, 2). It is estimated that there are
108  TCRs in the human naive T-cell pool (3), a number
that is dwarfed by the immense array of potential antigenic
peptides that could be encountered (4). Evolution appears to
have solved this conundrum by endowing T-cells with an
extremely high degree of cross-reactivity (4–6). A corollary of
this hypothesis is that multiple TCRs can recognize individual
peptide-MHC (pMHC) antigens. Indeed, there is now evidence
that antigen-specific T-cell populations, although frequently
skewed toward dominant clonotypes present at high frequency,
can be highly polyclonal (7–9).
To date, vaccine strategies have aimed to induce the largest
T-cell responses possible without specific consideration of the
individual clonotypes that constitute each response. However,
emerging evidence suggests that the quality of a T-cell
response, determined at the clonotypic level, might be more
important than quantity, defined as the overall magnitude of a
specific T-cell population (10–12). For example, clonotype
usage within two different codominant simian immunodefi-
ciency virus-specific CD8 T-cell responses in Mamu A*01
rhesusmacaques can determine patterns of viral escape by anti-
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gen mutation during acute infection and act as a molecular
signature of subsequent disease course (13, 14). Adoptive trans-
fer experiments further underscore the fact that T-cell clono-
types recognizing the same antigen should not be viewed on an
equal basis as their individual sensitivity to antigen density at
the target cell surface is a critical determinant of in vivo efficacy
(15). Thus, it seems that the efficacy of an antigen-specific
T-cell response and its clonotypic architecture are inexorably
linked. Consequently, the best vaccines should aim to induce
the most effective T-cell clonotypes.
In many cases, the most effective T-cells are those that rec-
ognize target cells bearing low densities of cognate pMHC on
their surface (10). Consistent with early studies using altered
peptide ligands (APLs) with weak binding affinities (16), our
own experiments using biophysically defined T-cell antigens
indicate that the best T-cell agonists are those that engage the
TCR with the highest affinities and for the longest dwell times
(17, 18). Similarly, transduction experiments using TCRs with
different affinities for defined natural antigens (19) also show,
across multiple systems, that T-cells expressing higher affinity
TCRs are more sensitive to antigen (17). Thus, TCRs with rel-
atively high affinities are preferable when a high level of sensi-
tivity to low antigen density is required. This feature becomes
all the more important in the case of neoplastic targets as
pMHC class I (pMHCI) antigen copy number at the cell surface
is often very low (20). In addition, TCRs that recognize “self”
tumor-associated antigens strongly are likely to be culled dur-
ing thymic selection; as a consequence, antitumor TCRs bind
their cognate pMHCantigens relativelyweaklywhen compared
with pathogen-specific TCRs (21). The importance of clono-
typic composition within antigen-specific T-cell populations
should therefore be taken into consideration when attempting
to design optimal vaccine strategies that aim to elicit effective
T-cell immunity.
Here, we examined a system that has been popular for ther-
apeutic vaccination and adoptive T-cell transfer for the treat-
ment of malignant melanoma, the leading cause of skin cancer-
related deaths worldwide. Melanoma immunotherapy efforts
have largely focused on an 18-kDa melanocyte-specific trans-
membrane protein called melanoma antigen A (Melan A), also
termed primary melanoma antigen recognized by T-cells
(MART-1) (22, 23), which represents a good candidate target
antigen because it is expressed by90% ofmelanomas (22, 23).
HLAA*0201-restrictedMelanA-specific CD8T-cells derived
frommelanoma patients primarily recognize the Melan A27–35
(AAGIGILTV) and Melan A26–35 (EAAGIGILTV) peptides
(24, 25). The AAGIGILTV peptide is the primary epitope
expressed on the surface of tumor-derived cells (26). There is a
large HLA A*0201-restricted Melan A-specific naive T-cell
pool available for manipulation in bothmelanoma patients and
healthy donors (27, 28). However, the natural antigens
AAGIGILTV and EAAGIGILTV are poorly immunogenic (29)
and, consequently, this system has become widely used to
champion the use ofMHC anchor-modified “heteroclitic” pep-
tides. Indeed, the heteroclitic peptide ELAGIGILTV has been
used in many published studies and several vaccination trials
(30–33). The ELAGIGILTV peptide variant binds to HLA
A*0201 with increased stability when compared with the two
natural peptides and exhibits heightened immunogenicity (29,
34, 35). The shorter LAGIGILTV peptide variant adopts a sim-
ilar bulged confirmation to ELAGIGILTV in the HLA A*0201
binding groove (36) and is also more immunogenic than its
natural AAGIGILTV counterpart (37). We have recently dem-
onstrated that TCRs specific for Melan A26–35 can distinguish
between the heteroclitic ELAGIGILTV variant and the natural
EAAGIGILTV peptide sequence (34). Furthermore, the ELA-
GIGILTV variant primes CD8T-cells in vitro that bear differ-
ent TCRs when compared with those primed in parallel with
the natural EAAGIGILTV peptide (34) despite the fact that
HLA A*0201-ELAGIGILTV and HLA A*0201-EAAGIGILTV
adopt similar unligated structures (36). Indeed, recent work by
Speiser et al. (33) has shown that vaccination with the natural
decapeptide (EAAGIGILTV) inducesT-cellswith superior lytic
activity against tumor cells when compared with those induced
by the commonly used heteroclitic ELAGIGILTV variant.
Thus, the use of anchor-modified heteroclitic peptides requires
careful re-evaluation to ensure that T-cells with the best spec-
ificity and sensitivity for the intended target are elicited (34).
The TCR repertoire of HLAA*0201-restrictedMelanA-spe-
cific CD8 T-cell populations is extremely diverse (34, 38–40)
and encompasses a spectrum of antigen recognition properties
that influences the ability of individual T-cells to recognize the
naturally expressedMelan A epitopes (41). To design an analog
peptide that stimulates functionally superior T-cell clonotypes,
we studied multiple Melan A-specific CD8 T-cell clones and
selected a candidate, MEL5, that recognized the dominant nat-
ural epitope, AAGIGILTV, at the lowest antigen density (34).
Unlike otherMelanA-specific TCRs, theMEL5TCRbound the
natural melanoma antigen with a dissociation constant (KD) of
14 M; this is one of the strongest affinities for TCR interac-
tions with natural self tumor antigens (21). We hypothesized
that CD8 T-cells with identical or similar specificities to
MEL5 might represent the most desirable targets for optimal
therapeutic vaccination (34). Accordingly, we used this model
system to design and test a methodology for priming high qual-
ityMelanA-specific CD8T-cells from the human naive T-cell
pool.
EXPERIMENTAL PROCEDURES
Melanoma Cell Lines—The HLA A*0201 melanoma cell
lines MEL 526 and MEL 624 have been described previously
(42, 43).
Generation and Maintenance of CD8 T-cell Clones and
Lines Specific for the HLA A*0201-restricted Melan A26–35
Antigen—TheMEL5 andMEL187.c5 CD8 T-cell clones were
generated and restimulated as described previously (18, 34).
CD8 T-cell lines specific for HLA A*0201-restricted Melan A
epitopes were generated by pulsing 6  106 peripheral blood
mononuclear cells fromhealthyHLAA*0201 individuals with
100 M peptide (ELAGIGILTV, AAGIGILTV, EAAGIGILTV,
or FATGIGIITV) for 1 h at 37 °C; cells were subsequently
washed and resuspended in RPMI 1640 supplementedwith 100
units/ml penicillin, 100g/ml streptomycin, 2mM L-glutamine,
and 10% heat-inactivated fetal calf serum (all Invitrogen) (R10
medium). Lines were tested for specificity using pMHCI
tetramer staining and subsequently maintained in R10 with
TCR-optimized Peptide Skewing of the T-cell Repertoire
37270 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 44•OCTOBER 26, 2012
 at CA
RD
IFF U
N
IV
ERSITY
 on Septem
ber 18, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
2.5% Cellkines (Helvetica Healthcare), 20 IU/ml IL-2, and 25
ng/ml IL-15 (both PeproTech). Throughout this study, altered
native sequence amino acid residues in antigenic peptides are
indicated by bold underlined text.
MIP-1 Release Assay—MEL5 or MEL187.c5 CD8 T-cell
clones were incubated overnight at 37 °C with C1R A*0201
(CIR A2) cells (44) pulsed prior to assay for 1 h with peptide at
various concentrations as indicated. After incubation, superna-
tant was harvested and assayed forMIP-1 by ELISA according
to the manufacturer’s instructions (R&D Systems).
Decamer Combinatorial Peptide Library Scan—The deca-
mer combinatorial peptide library (CPL) contained a total of
9.36  1012 ((10  19)  199) different decamer peptides (45,
46) and was divided into 200 different positional scanning pep-
tide mixtures (47). Prior to assay, MEL5 CD8 T-cells were
washed and rested overnight in R10 medium. For CPL screen-
ing, 6  104 C1R A2 cells were pulsed with various peptide
librarymixtures at 100g/ml in duplicate for 2 h at 37 °C. After
peptide pulsing, 3 104 MEL5 CD8 T-cells were added, and
the assay was incubated overnight at 37 °C. Subsequently, the
supernatant was harvested and assayed for MIP-1 by ELISA
according to the manufacturer’s instructions (R&D Systems).
pMHCI Tetramer Staining and Flow Cytometry—Soluble
biotinylated pMHCI monomers were produced as described
previously (48). Tetrameric pMHCI reagents were constructed
by the addition of either R-phycoerythrin (PE)-conju-
gated streptavidin (Invitrogen) or allophycocyanin-conjugated
streptavidin (ProZyme) at a pMHCI:streptavidin molar ratio of
4:1. For staining, 5 104 clonal CD8 T-cells or Melan A-spe-
cific line cells were incubated with fluorochrome-conjugated
tetramer (10 g/ml) for 20 min at 37 °C and then stained with
either allophycocyanin-conjugated anti-human CD8 (clone
RPA-T8; BDBiosciences) or fluorescein isothiocyanate (FITC)-
conjugated anti-humanCD8 (clone SK1; BDBiosciences) and 5
l of 7-amino-actinomycin D (Via-Probe; BD Biosciences) for
30min at 4 °C. In some instances, Pacific Blue-conjugated anti-
human CD14 (clone Tuk4; Invitrogen) and Pacific Blue-conju-
gated anti-human CD19 (clone SJ25-C1; Invitrogen) were used
to exclude monocytes and B-cells from the analysis. For TCR
V analysis, CD8 T-cell lines were incubated with LIVE/
DEAD fixable aqua amine-reactive fluorescent dye (Invitro-
gen) for 15min at room temperature, washed once, and stained
with allophycocyanin-conjugated tetramer (either HLA
A*0201-EAAGIGILTV or HLA A*0201-ELAGIGILTV). Cells
were then stained with peridinin chlorophyll protein (PerCP)-
conjugated anti-humanCD8 (clone SK1; BDBiosciences) and a
panel of anti-human V antibodies for 30 min at 4 °C. Cells
were subsequently washed twice and resuspended in PBS. Data
were acquired using a FACSCanto II flow cytometer (BD Bio-
sciences) and analyzed with FlowJo software (Tree Star Inc.). A
panel of 23 anti-human V antibodies was used in this study:
anti-humanV 1, 2, 5.1, 7.1, 7.2, 8, 13.1, 13.2, 13.6, 14, 17, 18, 20,
and 21.3 (Beckman Coulter) and anti-human V 3, 5.2, 5.3, 9,
11, 12, 16, 22, and 23 (Immunotech). Anti-human V 1 (clone
2406), 2 (clone 2407), 3 (clone 2372), 5.1 (clone 1552), 5.2 (clone
1482), 7.1 (clone 2408), 8 (clone 1233), 11 (clone 1586), 12
(clone 1587), 13.1 (clone 1554), 13.6 (clone 1330), 14 (clone
1558), 16 (clone 1560), 17 (clone 1234), 20 (clone 1562), 21.3
(clone 1483), and 22 (clone 1484) were conjugated to FITC;
anti-human V 5.3 (clone 2002), 7.2 (clone 3604), 9 (clone
2003), 13.2 (clone 3603), 18 (clone 2049), and 23 (clone 2004)
were conjugated to PE. Tetramer association and decay assays
were performed as described previously (18, 49).
Surface Plasmon Resonance Analysis—Soluble TCRs derived
from theMEL5 andMEL187.c5 CD8T-cell clones wereman-
ufactured as described previously (21, 50). Binding analysis by
surface plasmon resonance (SPR) was performed using a BIA-
core 3000TM equipped with a CM5 sensor chip (51). Between
200 and 400 response units of biotinylated pMHCIwere immo-
bilized to streptavidin, which was chemically linked to the chip
surface. The pMHCI was injected at a slow flow rate (10
l/min) to ensure uniform distribution on the chip surface.
Combined with the small amount of pMHCI bound to the chip
surface, this reduced the likelihood of off-rate-limiting mass
transfer effects. The MEL5 TCR and MEL187.c5 TCR were
purified and concentrated to100 M on the same day of SPR
analysis to reduce the likelihood of TCR aggregation affecting
the results. For equilibrium analysis, eight serial dilutions were
carefully prepared in triplicate for each sample and injected
over the relevant sensor chips at 25 °C. The TCRs were injected
over the chip surface at a flow rate of 45 l/min. Results were
analyzed using BIAevaluation 3.1TM, Microsoft ExcelTM, and
Origin 6.1TM. The equilibrium binding constant (KD) values
were calculated using a nonlinear curve fit (y (P1x)/(P2 x)).
Specific Lysis Assay—For chromium release assays, 2  103
MEL 526 or MEL 624 target cells were labeled with 30 Ci of
51Cr (PerkinElmer Life Sciences) per 106 cells for 1 h at 37 °C.
Targets were cultured alone to determine spontaneous release
andwith Triton X-100 (Sigma-Aldrich) at a final concentration
of 5% to determine total release. HLA A*0201-restricted CD8
T-cells specific for Melan A26–35 were plated out in a final vol-
ume of 200l of R10 at E:T ratios of 25:1 to 0.1:1 with respect to
each target; this ratio was determined by HLA A*0201-EAA-
GIGILTV tetramer staining immediately before assay to quan-
tify the percentage of antigen-specific CD8 T-cells in each
line. The plates were then incubated for 4 h at 37 °C. For each
sample, 20l of supernatantwas harvested after incubation and
mixed with 150 l of OptiPhase supermix scintillation mixture
(PerkinElmer Life Sciences). Data were acquired using a liquid
scintillator and luminescence counter (MicroBeta TriLux;
PerkinElmer Life Sciences)withMicroBetaWindowsWorksta-
tion software (PerkinElmer Life Sciences). Specific lysis was cal-
culated according to the following formula: (experimental
release spontaneous release/total release spontaneous re-
lease) 100.
pMHCI Stability Assays—SPR was used to determine
pMHCI stability as described previously (34, 35). Circular
dichroism measurements of thermal stability were performed
with purified, soluble HLAA*0201-peptide using an Aviv 62DS
spectrometer monitoring a wavelength of 218 nm as described
previously (52). Solution conditions were 20 mM phosphate, 75
mM NaCl, pH 7.4. Protein concentrations were 10 M. A tem-
perature increment of 0.3 °C/min was used. As unfolding is
irreversible, data were normalized and fitted to a six order pol-
ynomial, and the Tm was taken as the midpoint of the fitted
curve.
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Crystallization, Diffraction Data Collection, and Model
Refinement—HLA A*0201-FATGIGIITV and HLA A*0201-
FLTGIGIITV crystals were grown at 18 °C by vapor diffusion
with the sitting drop technique, using a Phoenix robot (Alpha
Biotech). Multiple attempts to cocrystallize MEL5 TCR/HLA
A*0201-FATGIGIITV failed. Crystals of HLAA*0201-FATGI-
GIITV and HLA A*0201-FLTGIGIITV appeared in 0.1 MMes,
pH 7.0, 0.2 M ammonium sulfate, and 20% PEG 8000. Data were
collected at 100 K on beamline IO3 at the Diamond Light
Source (Oxfordshire,UK) using awavelength of 0.976Åwith an
Area Detector Systems Corporation Q315 CCD detector.
Reflection intensities were estimated with XIA2 using the
MOSFLM or XDS packages (53), and the data were scaled,
reduced, and analyzedwith SCALAand theCCP4 package (54).
The structures were solved with Molecular Replacement using
PHASER (55). Model sequences were adjusted with COOT
(56), and the models were refined with REFMAC5 (57). Graph-
ical representations were prepared with PyMOL (58). Data
reduction and refinement statistics are shown in supplemental
Table S1.
RESULTS
Melan A-specific CD8 T-cells Exhibit Substantial Diversity
in Their Ability to Recognize Natural Tumor Epitopes—It is
established that the ELAGIGILTV and EAAGIGILTV peptides
exhibit differential binding to HLA A*0201 (34, 59). The dom-
inant natural peptide at the melanoma surface, AAGIGILTV
(26), does not contain an optimal primary anchor residue for
HLA A*0201 binding toward the N terminus; thus, the HLA
A*0201-AAGIGILTV complex is likely to be unstable. To test
this, we investigated the secondary structure of HLA
A*0201-AAGIGILTV using circular dichroism over a range
of temperatures (supplemental Fig. S1A). As expected, theHLA
A*0201-AAGIGILTV complex was less stable than HLA
A*0201-EAAGIGILTV and considerably less stable than
HLA A*0201-ELAGIGILTV, with denaturation temperatures
of 37, 39, and 55 °C, respectively. The enhanced stability ofHLA
A*0201-ELAGIGILTV when compared with HLA A*0201-
EAAGIGILTV and HLA A*0201-AAGIGILTV (supplemental
Fig. S1A) (34, 59) likely translates into substantially higher cell
surface densities of HLA A*0201-ELAGIGILTV at any given
exogenous peptide concentration relative to the natural anti-
gens. Indeed, this difference in antigen density may contribute
to the ability of some CD8 T-cell lines to recognize ELA-
GIGILTV at lower exogenous concentrations when compared
with the natural peptides (60).
Our recent work has shown that individual TCRs can exhibit
substantially different binding to HLA A*0201-EAAGIGILTV
and HLA A*0201-ELAGIGILTV, thereby demonstrating a
preference for either type of antigen (34). The two extremes of
variant recognition that we have observed with HLA A*0201-
restrictedCD8T-cell clones are depicted in supplemental Fig.
S1, B andC. Most clonotypes exhibit a recognition pattern sim-
ilar to MEL187.c5 (60), which recognizes the ELAGIGILTV
heteroclitic variant at lower peptide concentrations than the
natural sequences. Despite this preference for the ELA-
GIGILTV peptide at the population level, however, relatively
rare individual clonotypes exist that do not conform to this
pattern (61). The MEL5 clone epitomizes this incongruity
and exhibits potent recognition of the dominant natural
AAGIGILTV peptide. Indeed, this clone appears to compen-
sate for the reduced HLA A*0201 binding of the natural EAA-
GIGILTV and AAGIGILTV peptides (supplemental Fig. S1B),
suggesting that the clonotypic TCR must bind with greater
affinity to these variants than to HLA A*0201-ELAGIGILTV.
Consistent with these predictions, the MEL5 TCR bound to
the natural epitope, HLAA*0201-EAAGIGILTV, with an affin-
ity that lay within the range normally observed for TCRs that
recognize pathogen-derived epitopes (KD 6.4 M) (Table 1)
(34). To the best of our knowledge, this is the strongest affinity
yet described for TCR binding to a non-MHC anchor-modified
self-derived peptide. The MEL5 TCR bound to HLA A*0201-
AAGIGILTV with a slightly weaker affinity (KD 14 M), but
this was still stronger than that observed for the HLA A*0201-
ELAGIGILTV complex (KD 17 M) (supplemental Fig. S1D
and Table 1). Thus, although the MEL187.c5 and MEL5 TCRs
bound to HLA A*0201-ELAGIGILTV with almost identical
affinities (Table 1), very different interactions were apparent
with the endogenous peptides, AAGIGILTV and EAA-
GIGILTV, which are presented on the melanoma cell surface.
TheMEL187.c5 TCR bound to HLAA*0201-AAGIGILTV and
HLA A*0201-EAAGIGILTV with dissociation constants of 94
and 42 M, respectively, compared with the corresponding val-
ues of 14 and 6.4 M for the MEL5 TCR (supplemental Fig. S1,
D and E and Table 1). Collectively, these data demonstrate that
theMEL5TCR is an outlier within the population of clonotypic
TCRs that are able to engageMelanA27–35 andMelanA26–35 in
the context of HLA A*0201 as it exhibits a preference for the
natural antigens over the heteroclitic variant.We reasoned that
T-cells bearing TCRs with specificities and binding affinities
similar to MEL5, which can recognize the dominant natural
antigen on the surface of melanoma cells efficiently, would rep-
resent the most effective clonotypes with which to target mel-
anoma cells. On this basis, we next devised a strategy to skew
the repertoire of HLA A*0201-restricted Melan A-specific
CD8 T-cells toward the MEL5 clonotype and those with sim-
ilar properties.
Generation of OptimizedMelan A26–35 Analogues That Pref-
erentially Activate CD8 T-cells with Superior Natural Tumor
Epitope Recognition Properties—CPL scan technology was used
to design a peptide with two key properties necessary for the
preferential induction of MEL5-like CD8 T-cells from the
naive pool. Specifically, we considered that the ideal TCR-opti-
mized peptide (TOP) for priming purposes should exhibit: (i)
enhanced binding to theMEL5 TCR and (ii) decreased binding
TABLE 1
Binding affinities of theMEL5 andMEL187.c5 TCRs toMelanApeptide
variants
Data are summarized from this study and Ref. 34.
Ligand
TCR binding KD
MEL5 MEL187.c5
M
HLA A*0201-ELAGIGILTV 17 18
HLA A*0201-EAAGIGILTV 6.4 42
HLA A*0201-AAGIGILTV 14 94
HLA A*0201-FLTGIGIITV 5.1 16
HLA A*0201-FATGIGIITV 3 35
TCR-optimized Peptide Skewing of the T-cell Repertoire
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to TCRs with similar specificities that mediate poor killing of
melanoma cells. A CPL scan of the MEL5 CD8 T-cell clone
(Fig. 1A) showed that a restricted number of amino acid com-
binations were recognized in the central region of the peptide
(residues 4–6), consistent with the fact that the TCRmakes the
majority of its peptide contacts with these residues (50). In con-
trast, recognition at peptide positions beyond this central core
was highly degenerate. Indeed, when the results of four differ-
ent individual CPL scans were combined, three of the top four
activating sublibraries contained a fixed amino acid that was
not in the central core and did not occur in the natural sequence
(Fig. 1B). Overall, the MEL5 TCR showed a preference for
amino acids phenylalanine, threonine, and isoleucine at posi-
tions 1, 3, and 8 of the antigenic peptide, respectively. These
amino acids do not occur in the natural peptide (Fig. 1).
Single amino acid substitutions in the ELAGIGILTV peptide
differentially altered recognition by the MEL187.c5 and MEL5
CD8 T-cell clones (Fig. 2A). In contrast, a triple substitution
(1F, 3T, and 8I) in the ELAGIGILTV peptide produced an ana-
log (FLTGIGIITV) that showed an enhanced ability to activate
both of these clones (Fig. 2B). However, the same triple substi-
tution (1F, 3T, and 8I) in the natural EAAGIGILTV peptide
produced an analog (FATGIGIITV) with different properties.
The FATGIGIITV peptide acted as a superagonist for the
MEL5 CD8 T-cell clone, which preferentially recognizes nat-
urally processed melanoma epitopes, but activated the
MEL187.c5 CD8T-cell clone poorly (Fig. 2C). This difference
between the FLTGIGIITV and FATGIGIITV peptides was
observed across several different effector functions (supple-
mental Fig. S2). Real time SPR-based analysis of HLA A*0201-
peptide complex stability (34) and HLA A*0201 cell surface
stability assays showed that HLA A*0201-FLTGIGIITV and
HLA A*0201-FATGIGIITV were more stable than the natural
HLA A*0201-EAAGIGILTV complex (t1⁄2  25, 13, and 8 h,
respectively; Fig. 3). In accordance with the HLA A*0201 pre-
ferred binding motif XLXXXXXXV/L (62, 63), the FLTGIGI-
ITV peptide was almost twice as stable in complex with HLA
A*0201 when compared with the FATGIGIITV peptide (Fig.
3A). Similar results were obtained using a T2 surface binding
assay (Fig. 3B).
The FATGIGIITV and FLTGIGIITV Peptides Bind Differen-
tially to theMEL5 andMEL187.c5 TCRs—The observation that
theMEL5 andMEL187.c5 CD8T-cell clones exhibited differ-
ential recognition of the FATGIGIITV and FLTGIGIITV pep-
tides prompted us to examine the biophysical basis for these
differences. Both the MEL187.c5 and the MEL5 TCRs bound
similarly to the common heteroclitic peptide complex HLA
A*0201-ELAGIGILTV (KD 18 M; Table 1). The triple-sub-
stituted heteroclitic FLTGIGIITV peptide in complex with
HLA A*0201 displayed stronger affinity interactions with both
the MEL5 (KD 5.1 M; Fig. 4A) and the MEL187.c5 (KD 16
M; Fig. 4B) TCRs, consistent with the observation that this
peptide activated both of the corresponding CD8 T-cell
clones more potently than the ELAGIGILTV peptide (Fig. 2B
and supplemental Fig. S2). In contrast, the triple-substituted
natural FATGIGIITV peptide in complex with HLA A*0201
displayed a substantially stronger affinity interaction with the
MEL5 TCR (KD3 M; Fig. 4C) and a weaker affinity interac-
tion with the MEL187.c5 TCR (KD 35 M; Fig. 4D), again
consistent with the activation data (Fig. 2C and supplemental
Fig. S2). These TCR binding properties at the monomeric level
translated into consistent patterns with respect to pMHCI
tetramer staining (Fig. 5, A and B) and kinetics (Fig. 5, C–F) at
the cell surface.
To investigate the structural mechanism governing the dif-
ferent biophysical and cellular effects of the FATGIGIITV,
FLTGIGIITV, and ELAGIGILTV peptides, we solved the
atomic structures of HLA A*0201-FATGIGIITV to 2.75 Å and
HLAA*0201-FLTGIGIITV to 2.35 Å (supplemental Table S1).
We compared the structure of HLA A*0201-FATGIGIITV to
our recently solved structure of theMEL5TCR in complexwith
HLA A*0201-ELAGIGILTV (Fig. 6A) (50). This comparison
suggested that a GluP1 to PheP1 mutation could lead to an
increase in bothFATGIGIITVandFLTGIGIITVpeptide affin-
ity for HLAA*0201 due to- stacking of the PheP1 side chain
FIGURE 1. Combinatorial peptide library scan of the MEL5 CD8 T-cell
clone. A, 6 104 C1R A2 cells were pulsed in duplicate with each sublibrary
fromadecamer CPL (100g/ml) at 37 °C. After 2 h, 3 104 clonalMEL5 CD8
T-cells were added and incubated overnight. Supernatantwas harvested and
assayed for MIP-1 by ELISA. Histograms show the S.D. of two duplicate
assays. Red bars indicate the “index” amino acid at each of the 10 positions.
B, summary box plot of CPL analysis. Numbers 1–10 indicate the amino acid
position; the sequence at the top shows the industry standard heteroclitic
ELAGIGILTV sequence. Combined data from four replicate assays are shown
in the box plot; the size and color of the amino acid in single-letter code indi-
cate howwellMEL5 CD8 T-cells responded to each sublibrary in accordance
with the key shown on the bottom.
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with that of Trp-167 in the MHC 2 domain, sandwiched into
position by the side chain of Tyr-59 in the MHC 1 domain
(Fig. 6C). A very similar result was seen with amodified version
of the WT1 peptide, in which substitution of the P1 residue
substantially enhanced HLA-A2 binding via - stacking (64).
Additionally, there could be new contacts between the PheP1
side chain and Gly-29 of the MEL5 CDR1 loop. Interestingly,
PheP1 in HLA A*0201-FATGIGIITV extended farther out of
the groove when compared with HLA A*0201-FLTGIGIITV
(Fig. 6B). This difference, probably a consequence of extra flex-
ibility allowed by theweaker interaction betweenAlaP2 and the
B-pocket of HLAA*0201, could enable closer contacts between
MEL5 and HLA A*0201-FATGIGIITV that would explain the
stronger binding affinity when compared with MEL5 and HLA
A*0201-FLTGIGIITV. In both theHLAA*0201-FATGIGIITV
and the HLA A*0201-FLTGIGIITV structures, the AlaP3 to
ThrP3mutation enabled a new interaction between ThrP3 and
HLA A*0201, which could explain the increased stability of the
peptide in the binding groove (Fig. 6D). However, it is unlikely
that the ThrP3 mutation could lead directly to new TCR con-
tacts. The ThrP8 to IleP8 mutation could mediate a new non-
polar bridge between the HLA A*0201-peptide complex and
the TCR, which would generate a genuine increase in affinity at
the expense of exposing a nonpolar side chain on the surface
of the unligated HLA A*0201-peptide structure (Fig. 6E).
The MEL5 TCR-optimized Analog Peptide FATGIGIITV
Can Prime Large Populations of Melan A-specific CD8 T-cells
from HLA A*0201 Peripheral Blood Mononuclear Cells—The
commonly used Melan A26–35 heteroclitic peptide ELA-
GIGILTV primes large populations of antigen-specific CD8
T-cells from the peripheral blood of healthy donors in vitro (Fig.
7A) and has been widely used in the clinic (30–33). However, it
has been recently shown that the natural decamer EAA-
GIGILTV peptide can trigger human CD8 T-cells with stron-
ger tumor reactivity when compared with the heteroclitic ELA-
GIGILTV peptide (33). Using direct ex vivo priming from
healthyHLAA*0201peripheral bloodmononuclear cell prep-
arations, we tested our hypothesis that the FATGIGIITV pep-
tidemight induce better quality CD8T-cell responses. In 6/10
donors, the FATGIGIITV peptide primed a larger population
of CD8 T-cells capable of recognizing the natural epitope
EAAGIGILTV when compared with priming with the hetero-
clitic ELAGIGILTV peptide (Fig. 7A and supplemental Table
S2). In the remaining four donors, the FATGIGIITV peptide
primed a comparable or smaller population of EAAGIGILTV-
specific CD8T-cells (supplemental Table S2). Importantly, in
FIGURE 2. Selection of Melan A26–35 analog peptides that preferentially activate the MEL5 CD8
 T-cell clone. 3 104 MEL5 or MEL187.c5 clonal CD8
T-cells were incubated overnight with 6 104 C1R A2 B-cells prepulsed with various concentrations of the indicated peptides. Supernatants were harvested
and assayed for MIP-1 by ELISA. A, recognition of the ELAGIGILTV peptide and the single-substituted variants FLAGIGILTV, ELTGIGILTV, and ELAGIGIITV.
B, recognitionof the ELAGIGILTV andFLTGIGIITVpeptides.C, recognitionof the ELAGIGILTV andFATGIGIITVpeptides. Error bars represent the S.D. of duplicate
assays and, in most cases, are smaller than the plot symbols.
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contrast to CD8 T-cells primed with either EAAGIGILTV or
AAGIGILTV, the FATGIGIITV peptide primed a population
of CD8 T-cells that stained with the HLA A*0201-EAA-
GIGILTV tetramer in all donors. The consistent priming
potency of the ELAGIGILTV peptide has made it the preferred
ligand for immunotherapeutic modulation in vivo. In this
regard, the observation that the FATGIGIITV peptide also
consistently primed antigen-specific CD8 T-cells, in some
cases in greater numbers than ELAGIGILTV (although this dif-
ference was not statistically significant), was unanticipated and
suggests that it could be a candidate for peptide vaccination.
Next, we tested the ability of FATGIGIITV-primed CD8
T-cells to kill tumor cells. Enhanced tumor lysis when com-
pared with ELAGIGILTV-primed CD8 T-cells was observed
in 3/7 donors with MEL 526 targets (Fig. 7B and supplemental
Fig. S3, E and G) and in 2/7 donors with MEL 624 targets (Fig.
7C and supplemental Fig. S3F). Comparable tumor responses
were observed in 3/7 donorswithMEL 526 targets (supplemen-
tal Fig. S3, A, C, and I) and 3/7 donors with MEL 624 targets
(supplemental Fig. S3, D, H, and J), and reduced tumor
responses were observed in the remaining three instances (sup-
plemental Fig. S3, B, K, and L).
Thus, the FATGIGIITV peptide primed a larger population
of CD8 T-cells when compared with the ELAGIGILTV
FIGURE 3. Binding ofMelan A26–35 analog peptides to HLAA
*0201. A, SPR
stability assay of HLA A*0201-EAAGIGILTV, HLA A*0201-ELAGIGILTV, HLA
A*0201-FLTGIGIITV, and HLA A*0201-FATGIGIITV loaded in parallel on the
sameBIAcore chip. B, T2 cell surface binding assays for eachpeptide shown in
Ausing 10Mpeptide (S.D. representative of two experiments). Both peptide
binding assays were performed as described previously (34). A standard Stu-
dent’s t test with equal variance and equal distribution revealed that the
mean fluorescence intensity (MFI) values for all comparisons were signifi-
cantly different to each other (p 0.05).
FIGURE 4. Binding affinity of Melan A26–35 analog peptides to the MEL5
andMEL187.c5TCRs.A, SPRequilibriumbindingof solubleMEL5TCR toHLA
A*0201-FLTGIGIITV. B, SPR equilibrium binding of soluble MEL187.c5 TCR to
HLA A*0201-FLTGIGIITV. C, SPR equilibrium binding of soluble MEL5 TCR to
HLA A*0201-FATGIGIITV. D, SPR equilibrium binding of soluble MEL187.c5
TCR to HLA A*0201-FATGIGIITV. The mean affinity for each interaction is
shown (n 2).
FIGURE 5. Heteroclitic and analog pMHCI tetramer binding and kinetics
at the surface of MEL5 andMEL187.c5 CD8 T-cells. A and B, steady state
tetramer binding analysis. 5  104 MEL5 (A) or MEL187.c5 (B) CD8 T-cells
were stainedwith either PE-conjugated HLA A*0201-ELAGIGILTV tetramer or
PE-conjugated HLA A*0201-FATGIGIITV tetramer (10 g/ml each) for 20 min
at 37 °C. C and D, tetramer on-rate analysis for MEL5 (C) and MEL187.c5 (D)
CD8T-cells.MFI,mean fluorescence intensity. E and F, tetrameroff-rate anal-
ysis for MEL5 (E) and MEL187.c5 (F) CD8 T-cells. C–F, experimental proce-
dures and curve fitting were performed as described previously (18, 49).
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“industry standard” in 6/10 donors. In the majority of donors
(79%), these primed CD8 T-cell populations exhibited either
an enhanced (36%) or a comparable (43%) ability to recognize
and destroy melanoma cells.
CD8 T-cell Populations Primed with the FATGIGIITV pep-
tide Are Clonotypically Distinct from Those Primed with the
ELAGIGILTV Peptide—Weused a panel of TCRV antibodies
to examineV usage inHLAA*0201-EAAGIGILTV tetramer
CD8 T-cell populations primed with the ELAGIGILTV het-
eroclitic variant and those primed with the FATGIGIITV pep-
tide. As might be expected, there was some overlap between
ELAGIGILTV-primed andFATGIGIITV-primedCD8T-cell
populations, with both showing preferential usage ofV 3, 13.2,
and 14 TCRs (Fig. 8). Interestingly, an over-representation of
V 14 usage in HLA A*0201-Melan A26–35 tetramer CD8
T-cells has been observed previously in ELAGIGILTV-primed
populations (40). However, each peptide also induced some
unique TCRs. For example, in donor 1 priming with FATGIGI-
ITV produced an HLA A*0201-EAAGIGILTV tetramer pop-
ulationwith 16.5%V 1, 11.4%V 9, and 7.8%V 13.1 usage; in
comparison, parallel priming with ELAGIGILTV generated a
population with 0% V 1, 3.2% V 9, and 2.1% V 13.1 usage
FIGURE 6.Structural analysis ofMelanA26–35 analogpeptides in complex
with HLA A*0201. A, structural comparison of HLA A*0201-ELAGIGILTV
(complexed with MEL5) and HLA A*0201-FATGIGIITV. The FATGIGIITV pep-
tide is shown as green sticks; the ELAGIGILTV peptide is shown as yellow sticks.
The MEL5 TCR chain is shown as a cyan graphic; the MEL5 TCR chain is
shown as an orange graphic. The HLA A*0201 helices have been omitted for
clarity. Importantly, conformational differences at peptide positions 1, 3, and
8 can be observed between the two peptides. These differences result in an
5-fold increase inbindingaffinity for theMEL5TCR.B, structural comparison
of HLA A*0201-FATGIGIITV and HLA A*0201-FLTGIGIITV. The FATGIGIITV
peptide is shownasgreen sticks; theFLTGIGIITVpeptide is shownas red sticks.
The MEL5 TCR chain is shown as a cyan graphic; the MEL5 TCR chain is
shown as an orange graphic. The HLA A*0201 helices have been omitted for
clarity. C, interaction of the PheP1 side chain (green sticks) of the FATGIGIITV
peptide with Trp-167 (blue sticks) in the MHC 2 domain and Tyr-59 (blue
sticks) in the MHC 1 domain. D, interaction of the ThrP3 side chain (green
sticks) of the FATGIGIITV peptide with Tyr-99 (blue sticks) in the MHC 2
domain. E, interaction of the IleP8 side chain (green sticks) of the FATGIGIITV
peptide with Trp-147 (blue sticks) in theMHC 2 domain. Data collection and
refinement statistics are shown in supplemental Table S1.
FIGURE 7. The optimized analog peptide FATGIGIITV primes large popu-
lations of melanoma-reactive CD8 T-cells. A, 6  106 peripheral blood
mononuclear cells from healthy HLA A*0201 individuals were pulsed with
100M peptide (ELAGIGILTV or FATGIGIITV) for 1 h at 37 °C; CD8 T-cell lines
were then grown out for 14 days and stained with PE-conjugated HLA
A*0201-ELAGIGILTV tetramer (left panels) or PE-conjugatedHLAA*0201-EAA-
GIGILTV tetramer (right panels) as described under “Experimental Proce-
dures.” Representative data are shown from one donor. Data from 10 addi-
tional donors are shown in supplemental Table S2. B and C, specific lysis of
MEL 526 (B) or MEL 624 (C) melanoma cells exposed to a CD8 T-cell line from
onedonor.Data fromsixadditionaldonorsareshowninsupplementalFig.S3.All
lysis assayswere set upusing a rangeof E:T ratios; effectorswere enumeratedby
stainingwiththeHLAA*0201-EAAGIGILTVtetramer.ErrorbarsareS.D. fromthree
experiments.
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(Fig. 8). Similar results were observed in the corresponding
HLA A*0201-ELAGIGILTV tetramer population (supple-
mental Fig. S4). The ELAGIGILTV-primed lines contained
HLA A*0201-EAAGIGILTV tetramer CD8 T-cells express-
ing V 7.1 and 21.3 that were rare in CD8 T-cell populations
expanded by the FATGIGIITV peptide (Fig. 8). Collectively,
these data show that subtle directed changes in the antigenic
peptide can alter the clonotypic repertoire of a T-cell response.
DISCUSSION
It is possible to expand and maintain large numbers of func-
tionally active tumor-specificCD8T-cells from the peripheral
blood of cancer patients and healthy donors by repeated pep-
tide-based vaccination. Despite this achievement, however,
objective clinical response rates in peptide vaccine trials to date
are low (3%) and not significantly higher than spontaneous
remission rates (65). One possible reason for this general lack of
success is the inadvertent induction of ineffective CD8 T-cell
clonotypes with low levels of sensitivity for the natural anti-
genic target that are unable to control tumor growth in vivo.
A popular approach for developing peptide candidates for
vaccination is to introduce substitutions at MHC anchor resi-
due positions that enhance the stability ofMHCbinding and, as
a result, immunogenicity in vivo. The majority of tumor-de-
rived HLA A*0201-restricted peptides do not contain an ideal
MHC binding consensus, and the use of anchor-modified het-
eroclitic peptides in these systems is widespread (34). We have
recently shown that TCRs can differentiate between natural
and anchor-modified heteroclitic peptides, enabling T-cells to
exhibit a strong preference for either type of antigen (34).
Accordingly, MHC anchor-modified heteroclitic peptides can
induce T-cell populations that are clonotypically distinct from
those induced by natural tumor epitopes (34, 66). As a result,
T-cells primed with MHC anchor-modified peptides can
exhibit poor cross-recognition of the naturally occurring tumor
antigen (33, 34). Thus, vaccinationwithMHCanchor-modified
peptides may elicit T-cells that exhibit suboptimal recognition
of the intended natural antigen and, consequently, impaired
functional attributes in vivo (34). It is therefore important that
theT-cell clonotypes induced by anyAPL-based immune inter-
vention are carefully evaluated after ex vivo priming to ensure
efficacy prior to studies in vivo.
An alternative approach to improve T-cell epitopes from
tumor-associated antigens is to enhance their engagement with
cognate TCRs. This approach has the advantage that the result-
ant APLs are highly likely to be viewed as “nonself” and may
therefore have an increased chance of breaking immune toler-
ance.However, the use of anyAPL also runs the risk of inducing
clonotypes that are ineffective at recognizing the native
sequence. Several previous studies have attempted this
approach and are therefore relevant to the current discussion.
Walden and colleagues (67) demonstrated that CPL scans can
be used to generate mimotopes for tumor-reactive CD8
T-cells when the natural antigen is unknown. A CPL-selected
mimotope that activated a cutaneous T-cell lymphoma-reac-
tive HLA B*08-restricted CD8T-cell clone was able to induce
populations of T-cells that killed tumor cells in vitro (67). Vac-
FIGURE8.FATGIGIITV-primedCD8T-cellsareclonotypicallydistinct fromthoseprimedbytheheterocliticpeptideELAGIGILTV.5104 cells fromHLA
A*0201-restricted Melan A-specific CD8 T-cell lines were incubated with LIVE/DEAD fixable aqua amine-reactive fluorescent dye for 15 min at room
temperature, washed once, and stained with allophycocyanin-conjugated HLA A*0201-EAAGIGILTV tetramer. Cells were then stained with peridinin chloro-
phyll protein-conjugated anti-human CD8 and a panel of anti-human V antibodies for 30 min at 4 °C. Corresponding data for HLA A*0201-ELAGIGILTV
tetramer cells from the same CD8 T-cell lines are shown in supplemental Fig. S4.
TCR-optimized Peptide Skewing of the T-cell Repertoire
OCTOBER 26, 2012•VOLUME 287•NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 37277
 at CA
RD
IFF U
N
IV
ERSITY
 on Septem
ber 18, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
cination of two HLA B*08 cutaneous T-cell lymphoma
patientswith thismimotope induced initial tumor regression in
both cases (68). As the natural antigen recognized by these
HLA B*08-restricted tumor-reactive CD8 T-cells remains
unknown, it has not been possible to compare the response
generated by the native peptide with that of the mimotope in
this system. Nevertheless, these studies serve as a good demon-
stration of how TOPs can be used in a clinical setting. Other
studies have attempted to use APL of known epitopes to gen-
erate better immune responses. For example, one multi-insti-
tutional effort used CPL screening of CD8 T-cell lines to gen-
erate an optimal mimotope of the HLA A*0201-restricted
HIV-1 p24 Gag-derived peptide TLNAWVKV (69). This
mimotope failed to mobilize clonotypes that were more effi-
cient at recognizing natural targets (69). A similar approach has
been attempted to improve CD8 T-cell responses to human
carcinoembryonic antigen (CEA). CEA is expressed in the
majority of colonic, rectal, gastric, and pancreatic tumors (70),
70%of lung carcinomas (71), and 50%of breast carcinomas (72),
and there has been interest in a CEA-derived, HLA A*0201-
restricted epitope (YLSGANLNL) known as CAP1 (73). Substi-
tution of CAP1 at position 6, a TCR contact residue, with
aspartic acid to generate the APL YLSGADLNL enhanced
CAP1-specific CD8 T-cell recognition in amplified lines by
100-fold when compared with the native CAP1 peptide (73).
This superagonist variant, designated CAP1-6D, induced sub-
stantially larger responses in vitro when compared with the
native sequence (73). Furthermore, CAP1-6D-generated CD8
T-cell lines killed CEA-expressing human tumor lines effi-
ciently (73). Subsequent studies in this system, however, dem-
onstrated that the predominant CD8 T-cells primed with the
CAP-6D peptide displayed restricted TCR usage and lower lev-
els of sensitivity for the natural antigen (74). Thus, previous
studies with TOPs have failed to improve either the functional
qualities of the selected clonotypes or the overall efficacy of the
T-cell response in comparison with the native antigen (33, 69).
Unlike the process described herein, however, these previous
approaches did not use improved ligands for the best T-cell
clonotype. The optimizedHIV-1 p24Gag-derived peptide used
by Kan-Mitchell and colleagues (69) was selected because it
exhibited improved recognition by multiple polyclonal CD8
T-cell lines. This approach does not optimize a ligand for a
specific and beneficial functional phenotype, and so is equally
likely to improve recognition by good and poor clonotypes
alike. Such “universal” optimizationmay also combine with the
selection of APL-specific clonotypes that recognize the natural
sequence poorly to ensure that although the magnitude of the
APL-induced response might far exceed that generated by the
natural antigen, the overall quality of the mobilized T-cell pop-
ulation with respect to recognition of the intended natural tar-
get will be inferior.
The approach adopted here incorporates some fundamental
differences to the attempts that preceded it. Most notably, we
started by selecting a CD8T-cell clonotype with superior nat-
ural target antigen recognition properties. In this way, we
hoped to skew the expanded CD8 T-cell population toward
clonotypes with optimal antitumor efficacy. We describe this
approach as “TCR-optimized peptide skewing of the repertoire
of T-cells” (TOPSORT). The primary natural Melan A-derived
antigen on the surface of melanoma cells, AAGIGILTV (26), is
an extremely poor immunogen. Accordingly, the highly immu-
nogenic MHC anchor-modified peptide ELAGIGILTV has
been widely adopted in the clinic (30–33). This approach has
failed, however, and it has become apparent that HLA A*0201-
ELAGIGILTV is recognized differently by TCRs when com-
pared with the natural antigen (34). Consequently, HLA
A*0201-ELAGIGILTV can induce populations of T-cells that
bear TCRs with poor reactivity against the natural antigen (34).
The naive Melan A-specific T-cell population is characterized
by a highly diverse TCR repertoire and, as a result, exhibits a
large degree of functional diversity.We selected aMelanA-spe-
cific CD8 T-cell clone (MEL5) that displayed potent recogni-
tion of the natural tumor epitopes EAAGIGILTV and
AAGIGILTV and then used CPL scan technology to identify
analog peptides that exhibited improved recognition by this
clonotype. The CPL scan data revealed that MEL5 exhibited a
preference for phenylalanine, threonine, and isoleucine at posi-
tions 1, 3, and 8 of the antigenic peptide, respectively. Insertion
of the triple mutation into the EAAGIGILTV peptide sequence
produced the FATGIGIITV peptide. Biophysical data demon-
strated that HLAA*0201-FATGIGIITV bound theMEL5 TCR
with an affinity 10-fold stronger than that measured for the
alternative MEL187.c5 TCR. These findings were confirmed
with cell surface pMHCI tetramer staining experiments. As a
consequence, the FATGIGIITV peptide was a poor stimulator
of the MEL187.c5 clone, which preferentially recognizes ELA-
GIGILTV, yet potently stimulated theMEL5 clone, which pref-
erentially recognizes the natural peptide antigens. Indeed, the
MEL5 TCR engaged the dominant natural antigen (HLA
A*0201-AAGIGILTV) with a relatively high affinity (KD 14
M), which explained the antitumor efficacy of theMEL5 clone.
The magnitude of the HLA A*0201-EAAGIGILTV tetramer
CD8 T-cell population primed by FATGIGIITV exceeded
that primed by ELAGIGILTV in 6/10 donors tested and was
comparable or reduced in 4/10 donors. Furthermore, FATGI-
GIITV-primed CD8 T-cells were clonotypically distinct from
those induced by the ELAGIGILTV peptide and were capable
of enhanced melanoma cell killing in 36% of donors. Notably,
clonotypic analysis has revealed that the MEL5 TCR -chain
(V 20.1) was not ubiquitously expressed in all donors (75).
Therefore, although FATGIGIITV improved antigen recogni-
tion by the Melan A-sensitive MEL5 clone, this clonotype
might be absent in some donors, which likely explains why this
approach was not universally superior when compared with
priming with ELAGIGILTV. Thus, the availability of highly
shared, or public, clonotypesmay dictate the overall applicabil-
ity of TOPSORT (76). It is not knownwhether there is an effec-
tive public clonotype for the HLA A*0201-AAGIGILTV
antigen.
The observation that the FATGIGIITV peptide elicits CD8
T-cell populations with a different clonotypic architecture
when compared with ELAGIGILTV raises the possibility that
some unwanted or autoreactive T-cell clonesmight be selected.
This seems unlikely, however, because the primed clonotypes
in both cases will have been through the same thymic editing
process. Combined with peripheral tolerance mechanisms,
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there is therefore no a priori reason to suspect that FATGIGI-
ITV-primed autologous T-cells will be more deleterious than
autologous T-cells primed with other natural or heteroclitic
peptides.
The TOPSORT process used to generate the FATGIGIITV
sequence selected in this study differs in a number of key
aspects from previous studies. These differences include: (i)
identification of a high quality T-cell clonotype from the poly-
clonal population induced by the natural antigen; (ii) selection
of a TOP superagonist for this clonotype; (iii) elimination of
mutations that favor both “good” and “bad” clonotypes; and (iv)
verification that superior functional qualities are induced in
TOP-primed responses relative to those primed by the natural
antigen. The work described here represents a proof-of-con-
cept study for the use of TOPSORT, although confirmation of
efficacy in vivo is still required. Nonetheless, combined with
emerging next generation sequencing strategies for compre-
hensive TCR repertoire analysis, it can be envisaged that this
approach might enable the rational design of individualized
peptide-based vaccines.
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